GlassScriptPhysician profile
John Tucker Allred
NPI 1356796866
$2,414.88
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.97 · 2022: $524 · 2023: $1,217 · 2024: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $418.42 | 2022-2024 | Ubrelvy, Botox, Qulipta |
| Teva Pharmaceuticals USA, INC. | $231.93 | 2021-2023 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $183.13 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $177.10 | 2023-2024 | Ultomiris, Soliris |
| Argenx US, INC. | $145.56 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $131.21 | 2023-2024 | |
| Abbott Laboratories | $105.84 | 2022-2023 | Infinity |
| Emd Serono, INC. | $103.61 | 2023-2024 | Mavenclad |
| Alnylam Pharmaceuticals INC. | $86.88 | 2024 | Onpattro |
| Celgene Corporation | $67.69 | 2023-2024 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $66.20 | 2023-2024 | Wainua |
| Pfizer INC. | $61.79 | 2023 | |
| Stryker Corporation | $60.74 | 2023 | Capri Corpectomy Cage System |
| Lundbeck LLC | $56.87 | 2023-2024 | Vyepti |
| Ucb, INC. | $49.81 | 2023 | Briviact |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $46.39 | 2023 | Wakix |
| Mdd US Operations, LLC | $41.47 | 2022 | |
| Sk Life Science, INC. | $40.39 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $36.02 | 2023-2024 | Rytary |
| Biogen, INC. | $34.36 | 2022-2024 | Plegridy, Tysabri, Vumerity |
| Impel Pharmaceuticals INC. | $33.84 | 2023 | Trudhesa |
| Genentech USA, INC. | $31.99 | 2023 | Ocrevus |
| Lilly USA, LLC | $28.81 | 2024 | Amyvid |
| Otsuka America Pharmaceutical, INC. | $25.85 | 2023 | Rexulti |
| Acadia Pharmaceuticals INC | $23.55 | 2023 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $22.95 | 2023 | |
| Csl Behring | $22.45 | 2022 | |
| Neurocrine Biosciences, INC. | $22.10 | 2023 | Ongentys, Ingrezza |
| Genzyme Corporation | $22.01 | 2022 | |
| Acorda Therapeutics, INC | $18.61 | 2023 | Inbrija |
| Biohaven Pharmaceutical Holding Company LTD. | $17.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Allred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.